≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Disorders of endocrine glands in diseases classified elsewhere

DOID EFO Endpoint Browser PheWeb

E4_ENDINOTH

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E35
  • Cause of death: ICD-10 — E35

2 out of 7 registries used, show all original rules.

64

4. Check minimum number of events

None

64

5. Include endpoints

None

64

6. Filter based on genotype QC (FinnGen only)

64

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E20-E35
Name in latin
Morbositates glandularum endocrinarum in morbis alibi classificatis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 359 201 156
Only index persons 303 172 131
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 48.72 48.00 49.57
Only index persons 47.76 46.75 49.08

-FinnGen-

Key figures

All Female Male
Number of individuals 64 35 29
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 48.06 51.56 43.83

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
57
Matched controls
571
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H01AC01
ATC
somatropin; parenteral
236.5
17.5
17
*
H02AB09
ATC
hydrocortisone; systemic
29.2
15.7
21
11
E35.8
ICD-10 Finland
Disorders of other endocrine glands in diseases classified elsewhere
+∞
11.9
11
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
18.1
11.7
18
14
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
36.2
11.4
14
5
ZX120
NOMESCO Finland
Intravenous
10.0
9.7
20
29
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
8.5
8
*
Z94.0
ICD-10 Finland
Kidney transplant status
26.7
8.4
11
5
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
52.5
8.0
9
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
6.8
7.8
21
45
301
Kela drug reimbursment
Growth hormone
91.5
7.6
8
*
L04AX01
ATC
azathioprine; systemic
11.2
7.6
14
16
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
19.0
7.6
11
7
A11CC03
ATC
alfacalcidol; systemic
19.0
7.6
11
7
127
Kela drug reimbursment
Transplant complication
14.8
7.5
12
10
E35.0
ICD-10 Finland
Disorders of thyroid gland in diseases classified elsewhere
+∞
7.4
7
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
9.3
7.3
15
21
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
16.6
7.2
11
8
RD210
NOMESCO Finland
NA
19.8
7.0
10
6
A12AA04
ATC
calcium carbonate; oral
45.6
6.9
8
*
602
Kela drug reimbursment
Children's severe malnutrition
14.8
6.9
11
9
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
6.3
6.8
19
42
K00.40
ICD-10 Finland
Postnatal enamel hypoplasia
16.9
6.7
10
7
M08.3
ICD-10 Finland
Juvenile polyarthritis (seronegative)
78.3
6.6
7
*
E34.39
ICD-10 Finland
Short stature, not elsewhere classified
+∞
6.4
6
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
+∞
6.4
6
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
+∞
6.4
6
*
E34.35
ICD-10 Finland
Abnormal growth retardation
+∞
6.4
6
*
186
Kela drug reimbursment
Growth retardation associated with renal failure (growth hormone)
+∞
6.4
6
*
E35.1
ICD-10 Finland
Disorders of adrenal glands in diseases classified elsewhere
+∞
6.4
6
*
7143C
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Juvenile chronic polyarthritis[POLYARTHRITIS JUVENILIS SERONEGATIVA]
+∞
6.4
6
*
Z63.7
ICD-10 Finland
Other stressful life events affecting family and household
9.8
6.2
12
15
H02AB04
ATC
methylprednisolone; systemic
6.1
6.1
17
37
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.3
6.1
20
53
WX408
NOMESCO Finland
General anesthesy, balanced
4.3
6.1
28
105
I35.0
ICD-10 Finland
Aortic (valve) stenosis
13.1
6.1
10
9

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
38
8.89
14.56
13.6
4.6
111.7
55.2
ng/l
0.60
23
33
12
18
7.97
7.91
2.8
1.8
5.4
8.2
u/l
0.37
12
13
11
16
8.09
7.40
2.8
1.9
17.2
13.9
iu/l
—
11
10
14
29
5.90
6.82
7.9
5.6
0.0
0.8
%
—
5
10
28
105
3.96
6.61
6.9
5.1
—
—
—
0
0
14
30
5.69
6.57
5.4
4.8
0.0
0.4
%
—
5
8
12
22
6.48
6.57
9.0
11.3
0.3
0.5
g/l
0.21
12
14
14
31
5.50
6.34
8.8
5.3
0.3
0.5
%
—
6
11
11
20
6.43
6.04
3.8
1.4
—
—
—
0
0
32
143
3.48
5.65
11.8
9.0
—
—
—
0
0
13
30
5.18
5.59
8.2
5.5
0.0
0.0
%
—
6
11
22
78
3.77
5.50
42.1
7.3
1.2
1.2
mmol/l
0.36
22
71
9
8
12.82
5.48
1.9
5.9
8.6
8.1
%
—
9
8
15
40
4.59
5.46
37.7
7.2
—
—
—
0
0
20
67
3.89
5.41
24.9
9.0
—
—
—
0
0
23
86
3.61
5.30
7.8
3.0
565.3
573.2
mosm/kgh2o
0.06
23
72
34
168
3.18
4.94
15.3
7.4
1.3
1.3
inr
—
8
50
9
11
9.30
4.73
2.4
1.3
—
—
—
0
0
7
5
15.46
4.69
1.6
2.4
—
—
—
0
0
7
5
15.46
4.69
1.6
2.4
—
—
—
0
0
7
5
15.46
4.69
1.6
2.4
—
—
—
0
0
7
5
15.46
4.69
1.6
2.4
—
—
—
0
0
43
249
3.22
4.66
23.1
7.4
0.7
0.7
%
0.01
43
230
8
8
11.20
4.66
3.3
4.3
3.7
3.2
e9/l
—
8
8
8
8
11.20
4.66
3.1
4.3
51.6
51.1
%
—
8
8
17
57
3.70
4.53
29.5
10.4
—
—
—
0
0
43
253
3.13
4.46
23.2
7.4
3.0
2.8
%
0.15
43
234
36
192
3.00
4.46
18.7
7.7
—
—
—
0
0
7
6
12.87
4.38
73.7
3.7
—
—
—
0
0
16
53
3.69
4.33
2.1
2.2
—
—
—
0
0
43
256
3.07
4.31
24.3
7.6
9.0
8.6
%
0.54
43
239
15
48
3.78
4.25
48.4
7.1
4.8
4.8
kpa
0.04
15
42
43
258
3.03
4.22
21.5
7.4
54.7
53.9
%
0.16
43
243
25
114
2.96
4.03
13.3
3.2
1.0
1.0
kg/l
—
8
19
11
29
4.37
3.99
10.3
4.7
1.2
1.2
mmol/l
0.02
11
22
12
34
4.11
3.99
59.3
8.5
10.5
9.8
kpa
0.82
12
29
34
184
2.81
3.98
12.9
3.4
—
—
—
0
0
39
228
2.82
3.92
13.1
3.6
0.0
0.0
estimate
—
9
33
7
8
9.64
3.87
2.4
5.3
79.3
77.3
%
—
7
8
39
229
2.80
3.87
16.1
5.1
0.0
0.0
estimate
—
9
34
43
266
2.88
3.85
23.7
7.5
29.3
31.4
%
0.55
43
250
6
5
13.03
3.84
4.5
28.4
65.0
176.3
g/mol
—
6
5
39
230
2.78
3.82
13.1
3.6
0.0
0.0
estimate
—
8
32
26
125
2.82
3.77
5.2
3.3
—
—
—
0
0
15
52
3.46
3.76
31.9
13.9
24.1
25.0
mmol/l
0.63
15
52
18
71
3.14
3.69
25.8
5.5
0.8
0.8
mmol/l
0.19
18
66
49
333
3.01
3.54
15.6
4.4
—
—
—
0
0
11
32
3.94
3.51
1.7
1.3
—
—
—
0
0
22
100
2.83
3.51
20.5
2.9
3.9
5.9
e6/l
0.52
22
91
7
10
7.69
3.46
4.6
6.1
—
—
—
0
0
33
186
2.60
3.44
21.3
4.2
30.2
67.9
e6/l
0.74
27
128
43
278
2.67
3.34
12.0
5.0
6.2
6.6
mmol/l
0.66
43
261
6
7
9.29
3.33
1.5
6.0
29.0
34.1
%
—
6
7
47
318
2.80
3.32
18.6
4.2
7.0
112.4
e6/l
—
6
5
18
76
2.90
3.25
14.8
2.3
12.0
12.8
umol/l
0.27
18
69
23
111
2.67
3.24
6.6
3.3
311.0
10175.0
umol/l
0.76
23
90
37
226
2.51
3.19
10.2
6.7
8.3
10.7
umol/l
1.99
37
212
50
353
2.90
3.19
17.2
7.1
101.7
93.3
u/l
0.34
50
323
15
59
3.01
3.05
4.5
1.8
—
—
—
0
0
27
146
2.47
2.98
12.3
3.6
—
—
—
0
0
6
9
7.21
2.93
12.7
3.7
—
—
—
0
0
23
118
2.48
2.82
17.0
3.8
0.0
0.0
estimate
—
9
31
27
150
2.38
2.78
5.2
2.5
—
—
—
0
0
6
10
6.48
2.76
19.7
16.8
—
—
—
0
0
51
379
2.70
2.67
7.6
3.8
15.3
14.7
pmol/l
1.19
46
333
25
137
2.35
2.63
4.8
2.8
—
—
—
0
0
5
7
7.62
2.59
13.4
3.7
11.5
8.4
kpa
—
5
7
5
7
7.62
2.59
13.6
3.9
7.4
7.4
ph
—
5
7
5
7
7.62
2.59
13.4
3.7
4.8
4.9
kpa
—
5
7
5
7
7.62
2.59
1.2
1.7
—
—
—
0
0
5
9
5.91
2.25
2.4
3.0
—
—
—
0
0
23
130
2.20
2.20
19.8
3.4
7.4
7.4
ph
—
8
18
21
115
2.23
2.16
17.8
3.4
—
—
—
0
0
7
21
3.61
2.03
4.0
1.4
397.1
347.3
mu/l
—
7
21
18
95
2.24
2.01
16.5
3.9
—
—
—
0
0
5
11
4.83
1.98
1.0
1.3
—
—
—
0
0
12
53
2.56
1.95
1.8
1.5
—
—
—
0
0
10
41
2.71
1.86
4.3
1.4
—
—
—
0
0
5
12
4.42
1.86
2.8
1.2
—
—
—
0
0
8
31
2.80
1.72
1.1
1.4
—
—
—
0
0
5
14
3.78
1.64
1.6
1.3
—
—
—
0
0
6
21
3.04
1.54
18.3
11.0
0.5
0.7
%
—
6
21
7
29
2.58
1.44
4.0
2.4
—
—
—
0
0
8
34
2.54
1.35
9.8
4.1
—
—
—
0
0
5
18
2.92
1.31
1.0
1.2
—
—
—
0
0
16
98
1.84
1.17
4.2
2.9
76.0
72.2
mg/l
—
9
57
5
21
2.49
1.11
1.2
1.0
—
—
—
0
0
56
503
1.91
0.98
48.3
15.2
94.0
71.6
umol/l
0.88
56
503
16
107
1.66
0.87
5.0
3.6
16.9
8.9
mg/mmol
—
9
60
6
32
1.96
0.84
1.3
1.2
—
—
—
0
0
6
33
1.90
0.81
3.3
2.5
—
—
—
0
0
5
25
2.08
0.74
1.2
1.0
—
—
—
0
0
5
26
2.00
0.72
5.8
8.0
0.6
1.2
%
—
5
26
5
26
2.00
0.72
5.8
8.0
0.7
0.7
%
—
5
26
55
500
1.71
0.70
32.9
12.1
—
—
—
0
0
7
43
1.70
0.69
1.7
1.5
—
—
—
0
0
10
64
1.67
0.63
2.2
1.6
—
—
—
0
0
6
37
1.68
0.57
1.0
1.3
—
—
—
0
0
10
66
1.61
0.56
1.2
1.2
—
—
—
0
0
10
143
0.64
0.56
4.3
2.8
—
—
—
0
0
21
165
1.41
0.54
3.6
3.1
23.7
26.8
ng/l
0.16
15
102
6
40
1.55
0.53
1.2
1.2
—
—
—
0
0
19
151
1.37
0.45
1.7
1.6
2.5
2.2
g/l
—
9
75
12
88
1.45
0.44
1.8
1.8
—
—
—
0
0
12
88
1.45
0.44
1.3
1.3
11.2
35.9
iu/ml
—
5
27
0
15
0.00
0.42
0.0
1.1
—
3.8
—
0
10
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
147.4
—
0
5
14
108
1.38
0.39
1.8
2.2
—
—
—
0
0
21
182
1.23
0.26
2.8
2.0
—
—
—
0
0
7
91
0.74
0.24
1.3
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.5
—
—
—
0
0
0
14
0.00
0.20
0.0
3.1
—
65.9
—
0
14
14
119
1.23
0.20
5.2
3.9
—
—
—
0
0
13
150
0.83
0.17
1.5
1.5
—
—
—
0
0
32
301
1.13
0.13
5.2
3.2
—
—
—
0
0
18
163
1.15
0.12
1.5
1.8
109.5
100.4
pmol/l
—
6
77
49
475
1.13
0.10
49.0
15.5
35.1
39.7
%
2.02
37
366
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
11.5
—
0
8
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
7
73
0.95
0.00
1.1
1.2
—
—
—
0
0
5
52
0.96
0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
4.1
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_ENDINOTH and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
E4_ENDINOTH 2.635 [1.58, 4.39] < 0.001
Birth year 0.989 [0.98, 1.0] 0.016

During the follow-up period (1.1.1998 — 31.12.2019), 51 out of 142 males with E4_ENDINOTH died.

Mortality risk

Mortality risk for people of age

years, who have E4_ENDINOTH.

N-year risk Females Males
1 No data 0.513%
5 No data 3.446%
10 No data 8.439%
15 No data 15.679%
20 No data 25.275%

Relationships between endpoints

↥

Index endpoint: E4_ENDINOTH – Disorders of endocrine glands in diseases classified elsewhere

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data